IA
TNXP icon

IFP Advisors’s Tonix Pharmaceuticals TNXP Stock Holding History

IFP Advisors’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.6K Buy
1,356
+1,056
+352% +$16.3K ﹤0.01% 2816
2025
Q4 		$4.69K Buy
300
+100
+50% +$1.84K ﹤0.01% 3450
2025
Q3 		$4.83K Buy
+200
New +$7.42K ﹤0.01% 3269
2025
Q2 		– Sell
-10,000
Closed -$1.52K – 5015
2025
Q1 		$1.52K Buy
+10,000
New +$203K ﹤0.01% 3233
2024
Q1 		– Hold
0
– -$1 – 3239
2023
Q4 		– Hold
0
– – – 3037
2023
Q3 		– Hold
0
– – – 3287
2023
Q2 		– Hold
0
– – – 3434
2023
Q1 		– Hold
0
– – – 3347
2022
Q4 		– Hold
0
– – – 4487
2022
Q3 		– Hold
0
– – – 4416
2022
Q2 		– Hold
0
– – – 4195
2022
Q1 		– Hold
0
– – – 4193
2021
Q4 		– Hold
0
– – – 3127
2021
Q3 		– Hold
0
– – – 3139
2021
Q2 		– Hold
0
– – – 3237
2021
Q1 		– Hold
0
– – – 2883
2020
Q4 		– Hold
0
– – – 3094
2020
Q3 		– Hold
0
– – – 1913

Other funds holding TNXP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

IFP Advisors's TNXP Position: Q1 2026 in Review

IFP Advisors increased its Tonix Pharmaceuticals (TNXP) stake by 352% in Q1 2026, buying an estimated $16.3K and bringing the position to 1,356 shares worth $18.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2816.

IFP Advisors first reported a position in TNXP in Q1 2025 and has held it in 4 quarters since. 81 funds tracked by Wall St. Rank hold TNXP as of Q1 2026.

  • IFP Advisors held 1,356 shares of Tonix Pharmaceuticals worth $18.6K as of Q1 2026.
  • IFP Advisors bought 1,056 Tonix Pharmaceuticals shares in Q1 2026, an estimated $16.3K.
  • Tonix Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q1 2026, its #2816 holding.
  • IFP Advisors first reported a position in Tonix Pharmaceuticals in Q1 2025 and has held it in 4 quarters since.
  • 81 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2026.

Based on IFP Advisors's 13F filing for Q1 2026, filed 13 Apr 2026.